Pneumocystis carinii pneumonia is frequently the first condition diagnostic of the acquired immunodeficiency syndrome (AIDS) among individuals infected with the human immunodeficiency virus (HTV) in the United States. In the Multicenter AIDS Cohort study, P. carinii pneumonia was the ATDS-defining disease in 27 percent of the cases in 1990-1991 (1) . As many as 80 percent of AIDS patients develop P. carinii pneumonia at some time during the progression of their disease, and up to 20 percent may die because of it (2) . During the course of the AIDS epidemic, multiple regimens have been introduced for the treatment and prevention of P. carinii pneumonia in patients with AIDS. Early in the epidemic, there appeared to be a significant increase in survival time after diagnosis with P. carinii pneumonia (3) . The cause of this increase has been attributed to improved therapeutic and prophylactic regimens as well as to earlier diagnosis of P. carinii pneumonia (4). It is not yet known whether these earlier trends toward improved survival have continued and if so, whether survival has differed significantly across subgroups of AIDS patients.
Previous investigations (3) (4) (5) have evaluated the potential relation between patient characteristics (such as gender, age, race/ethnicity, mode of HTV transmission, CD4 count at diagnosis) and survival among patients with P. carinii pneumonia. The present investigation was undertaken using AIDS surveillance data in California to determine whether the previously reported rapid improvements in survival after P. carinii pneumonia diagnosis have continued, to examine the relation of available covariates to survival in the past decade, and to identify subgroups of ADDS patients with meaningfully different survival experiences.
MATERIALS AND METHODS

Sampling frame
The Office of AIDS of the California Department of Health Services, in cooperation with the Centers for Disease Control and Prevention, maintains a registry of all reported cases of AIDS in the state of California. This registry contains information submitted by all county health departments within the state. For each patient, multiple variables are recorded, including in part the following: date of birth, date of AIDS diagnosis, gender, race/ethnicity, probable mode of HTV transmission, date of death (if deceased), ZIP code of residence, and specific AIDS-defining condition(s). Additionally, the certainty of a patient's diagnosis with P. carinii pneumonia is recorded as presumptive versus definitive. Patients whose P. carinii pneumonia diagnosis was confirmed by microscopy are classified as definitive cases; patients whose P. carinii pneumonia diagnosis was made by all other clinical means are classified as presumptive cases. CD4 lymphocyte counts were reported with increasing frequency since the late 1980s, although this test was neither universally performed nor reported before the 1993 change in AIDS definition (6) . Dates of death are regularly updated by local county health departments and by the Office of AIDS using both the California Death Registry and the National Death Index.
Inclusion and exclusion criteria
From this registry, using data received as of April 30, 1995, all AIDS patients ever reported to have had P. carinii pneumonia in California were identified (n = 32,199). Patients were included in this analysis if P. carinii pneumonia was both the first and only AIDS-defining condition during the initial 6 months after AIDS diagnosis (to minimize the known impact of comorbid conditions on survival (4)); if the date of P. carinii pneumonia diagnosis was between January 1, 1983, and December 31, 1992; and if the individual's age on the date of P. carinii pneumonia diagnosis was 18 years or greater. Patients were excluded if the date of P. carinii pneumonia diagnosis was unknown or if the date of P. carinii pneumonia diagnosis was later than the date of death (i.e., postmortem diagnosis). A total of 19,607 patients were eligible for analysis after applying these criteria.
Regions of California
In this analysis, patients were classified into six regions of California based on their county of residence at the time of P. carinii pneumonia diagnosis. Each of the counties of San Francisco, Los Angeles, and San Diego was coded as one region. The "Bay Area" was defined as the counties of Alameda, Contra Costa, Mann, Napa, San Mateo, Santa Clara, Solano, and Sonoma. The "Southern Metropolitan" region was defined as the counties of Orange, Riverside, and San Bernardino. All remaining counties were grouped into the category "Other."
Survival analyses
Patients were grouped initially into quarterly cohorts based on the date of P. carinii pneumonia diagnosis (first quarter of 1983 labeled as "831," second quarter of 1983 labeled as "832," and so forth throughout this paper). Survival time was defined as the time (in months) from the month of P. carinii pneumonia diagnosis until death. Patients were censored as of December 31, 1993, if no death date was present in the registry or if the date of death was later than this date. This censoring date provided 1 year of potential follow-up time for the last patients enrolled in the study. Patients who died during the same calendar month in which they were diagnosed with P. carinii pneumonia were coded as surviving for 0.5 months.
Two approaches were used to examine the impact of temporal trends on the relation between the covariates of interest and survival after P. carinii pneumonia diagnosis. First, using Kaplan-Meier analysis, estimates of median survival and the proportions of patients surviving 3, 12, and 24 months after diagnosis were obtained for each quarterly cohort and plotted against the quarter of diagnosis. Visual examination of this plot was used to identify periods of time when survival experience of the quarterly cohorts of patients was either relatively constant or changing. These periods of time were then used to stratify the patients for additional analyses. The relation between the covariates (gender, age, race/ethnicity, mode of HTV transmission, region of diagnosis, CD4 lymphocyte count) and survival were then modeled for each period using Cox proportional hazards models. Estimates of median survival and the proportion of patients alive at 3, 12, and 24 months after diagnosis were calculated for each level of these categorical covariates. Cox proportional hazards models were fit individually for each covariate within each of the time periods examined. One Cox model that utilized all of the available covariates was also fit to the data for each period. The assessment of the proportional hazards assumption and the determination of an appropriate functional form for continuous variables was done using Martingale residuals (7) . Potential interactions between covariates were examined using recursive partitioning (see below).
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Data management was done using PC-SAS (8) . Kaplan-Meier estimates of survival and Cox proportional hazards models were obtained with STATA for Windows (9) . Residual analyses to test the assumption of proportional hazards and to examine the functional form of variables included in the Cox models were conducted using S-PLUS (10).
Subgroup analyses and recursive partitioning
Proportional hazards models provide estimates of the effects of each covariate on the sample as a whole. There may be important subgroups in the sample for which the summary estimate is not appropriate, a phenomenon classically described as interaction. The traditional approach to addressing this problem is to create interaction terms for inclusion in survival models or stratifying the data and analyzing certain subgroups separately. This approach requires the investigator to decide a priori which interactions are most important and to examine them within a model. One alternative to this approach is the use of tree-structured (recursive partitioning) analysis.
The identification of prognostic subgroups with distinct survival prospects is the thrust of tree-structured (recursive partitioning) survival analysis. While recursive partitioning has enjoyed widespread use with continuous (regression trees) or categorical (classification trees) outcomes (11) , its extension and application to censored survival data are more recent (12) (13) (14) . In recursive partitioning analysis of survival data, the entire sample is first split into two subgroups. The particular split chosen is selected from a multitude of allowable splits as one that optimizes a criterion function. We maximize the two-sample log rank statistic as that function. Thus, the two resultant subgroups have maximally distinct survival as measured by the log rank statistic. Allowable splits are defined in terms of the covariates. For ordered covariates (continuous or ordered categorical), the split results from a binary (yes/no) question that preserves order (e.g., "Is age £ 37?"). All cutpoints (here 37) in the range of the covariate in question (here age) are examined. For unordered categorical variables (e.g., race), splitting into any subset of the categories is allowed (e.g., "Is race white or Hispanic?"). Each covariate and all of its associated allowable splits are examined in turn, in no necessary order. After creating two new subgroups according to the best split (i.e., with maximal log rank statistic), the entire process is repeated on each of these subgroups. This initial partitioning or treegrowing phase terminates at subgroups having too few patients (here we used <50) or a proportion of censored observations that is too high (here we used >70 percent). The values of these a priori selected parameters is not critical. The objective is to obtain a large, possibly overfitted tree. The idea is that by initially growing a large tree, we capture all putatively important subgroups. Rigid stopping rules, while potentially avoiding "insignificant" splits, can also preclude the emergence of such important subgroups (11) . A second, pruning phase pares this large tree to remove the unimportant splits. Different methods for effecting pruning have been proposed; we use a graphical approach described in detail by Segal (15) . The subgroups that remain after pruning, and the sequence of splits used to create them, constitute the final tree model. These prognostic subgroups can then be compared and used as strata in subsequent analyses (11) (12) (13) (14) (15) (16) .
Availability of CD4 counts
The level of a patient's CD4 count is widely believed to be related to survival. These counts, however, became widely available only during the latter part of this investigation (April 1988 through December 1992). Therefore, CD4 counts could not be included in all analyses; separate analyses of patients with CD4 counts available are also presented. The relation between availability of a CD4 count (in addition to the level of the CD4 count) and survival was studied. CD4 counts were included only when they had been determined within 90 days of the date of P. carinii pneumonia diagnosis.
RESULTS
A total of 19,607 patients had a diagnosis of P. carinii pneumonia as a presenting condition for AIDS in California from January 1983 through December 1992 and met the inclusion criteria of the study. Among the 14,208 (72 percent) patients reported to have died on or before the censoring date (December 31, 1993), the longest survival time was 94 months (7.8 years). Among the 5,399 (28 percent) patients believed to be alive on the censoring date, the longest observed survival time was 116 months (9.7 years). In figure 1 is presented the median survival for each quarterly cohort of newly diagnosed P. carinii pneumonia patients during this 10-year period. In figure 2 is presented the 3-, 12-, and 24-month survival experience of these patients. Using the data from these two figures, the patients were divided into four periods by visual inspection: January 1983 through June 1986 (period 1); July 1986 through March 1988 (period 2); April 1988 through June 1991 (period 3); and July 1991 through December 1992 (period 4). These periods form the basis for subsequent analyses of the re- 
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Quarter of diagnosis The distribution of characteristics among the P. carinii pneumonia patients changed during the 10-year period of the study (table 1) . Homo-and bisexual males represented 81 percent of the population during the first period (January 1983 through June 1986) and 73 percent during the fourth period (July 1991 through December 1992). There was an increase in the proportion of P. carinii pneumonia patients with a history of injection drug use (as a mode of exposure to HTV) from period 1 (2.4 percent) to period 4 (10.4 percent). Similarly, the proportion of patients with heterosexual contact increased from 0.8 percent in period 1 to 3.6 percent in period 4. The percentage of female P.
carinii pneumonia patients increased from 2 to 6 percent from the first to the fourth periods. During the first period, whites represented 79 percent of the patients whereas blacks and Hispanics together formed 19 percent; by the fourth period, whites represented 62 percent of the patients whereas blacks and Hispanics together represented 36 percent. Early in the epidemic, San Francisco accounted for 46 percent of the P. carinii pneumonia patients; by the fourth period, only 24 percent of the patients were from San Francisco. CD4 lymphocyte counts became widely available only during the third and fourth periods. Fifty percent of the patients had CD4 counts ^50 cells/mm 3 at the time of diagnosis. 120 Colford et al.
Kaplan-Meier survival analyses
In both figures 1 and 2, there is evidence of rapidly improving survival during period 2. Both figures suggest that there was very little improvement in survival during period 3. The different survival experiences of the four periods are presented in the figure 3 KaplanMeier plot. Estimates from the Kaplan-Meier analyses for each of the covariates during each of the periods are presented in table 2 (median survival in months) and table 3 (percentage alive 3, 12, and 24 months after diagnosis of P. carinii pneumonia).
The upward trend in 12-and 24-month survival during period 4 (July 1991 through December 1992, figure 2 ) must be evaluated with caution; reporting delays for deaths may inflate the number of patients diagnosed during period 4 who were classified as being alive on the censoring date (December 31, 1993). As death reports progress through national tracking systems and are captured by the California HTV/AIDS surveillance registry, survival estimates may be adjusted downward. This occurs because previously censored patients are reclassified as deceased. The increases seen in 12-and 24-month survival during period 4 (figure 2) are probably due to these delays in the reporting of deaths.
Proportional hazards models
A proportional hazards model of survival is presented in table 4 for the patients diagnosed with P. carinii pneumonia during period 3 (April 1988 through June 1991). This period was chosen for detailed examination because sufficient time has elapsed so that reporting delay (of deaths) is not a likely problem and because the overall survival estimate for the population was stable throughout this period (figures 1 and 2 ). Similar models for periods 1, 2, and 4 were constructed (data not shown); there were no differences in the resulting inferences based on analysis of these other periods.
Because of the striking difference in survival noted between patients with and without CD4 counts (tables 2 and 3), separate univariate and multivariate proportional hazards models are presented for each group in table 4. The model for patients with CD4 counts available also includes the level of the CD4 count itself as a covariate. In both the univariate and multivariate models, a strong trend toward elevated relative hazard was noted across the four age categories with patients aged £:60 years compared with those aged 18-39 years at diagnosis having a relative risk (hazard) of 2.04 (95 percent confidence interval 1.77-2.34) among the patients without CD4 counts available. Among the patients with CD4 counts, the corresponding relative risk (hazard) was 3.37 (95 percent confidence interval 1.65-6.89). Age, CD4 count (among the group of patients having a CD4 count), and certainty of the P. carinii pneumonia diagnosis (definitive vs. presumptive) were the only variables consistently related to survival in the models constructed. With one exception, there was little difference in the relative associations between the covariates studied and survival Quarter of diagnosis 
Recursive partitioning
The recursive partitioning analysis was performed on the patients diagnosed with P. carinii pneumonia during period 3 (April 1988 through June 1991). This period was selected because the stability of the survival estimates during this period (figures 1 and 2) makes it unlikely that dramatic changes in therapy or diagnosis were affecting survival. The recursive partitioning analysis identified three terminal nodes or subgroups with significantly different survival experiences (table 5) . The three terminal nodes were defined by the availability of CD4 count and patient age at diagnosis of P. carinii pneumonia: group 1 (no CD4 count available and age 18-40.8 years); group 2 (no CD4 count available and age 40.9-80.7 years); and group 3 (CD4 count available). These three subgroups have median survival times of 19, 14, and 40 months, respectively (table 5 ). The median survival of the levels of the remaining covariates (i.e., those not used to split the data) are also shown in this table. The results of the recursive partitioning analysis support the approach we used in the proportional hazards model of creating separate models for the patients with and without CD4 counts (table 4) . In both analyses, the availability of a CD4 count was the single factor most strongly related to survival. Finally, we determined from the tree that there was no need to investigate additional interactions among covariates in models in which CD4 count was available (figure 4). When a survival tree was constructed for all 19,607 patients in the model (data not shown), the resulting tree indicated a need to split (at several levels) based on the date of P. carinii pneumonia diagnosis. The suggested splits based on date of diagnosis were very close to the ones initially chosen to define the periods of the study by visual inspection using figures 1 and 2.
DISCUSSION
The major findings of this investigation are as follows: After a period of rapid increase in survival (period 2, July 1986 to March 1988), there is no evidence of any more improvement in survival after the diagnosis of P. carinii pneumonia in California. In addition, there are striking differences of undetermined cause in the survival of patients with and without reported CD4 counts. Other important findings are that age at diagnosis, certainty of P. carinii pneumonia diagnosis (presumptive vs. definitive), and level of CD4 count (when available) were consistently related to survival among these patients. Additionally, patient race, mode of HTV exposure, location of residence at time of diagnosis, and gender were not related to survival.
As has been noted by others (17) , when interpreting survival data based on public surveillance systems, it is important to remember that patients classified as "alive" are more accurately defined as having "no report received of having died," since no active surveillance is performed to confirm living status among the censored patients. Although public surveillance data do not permit analyses to determine whether systematic differences exist in the surveillance follow-up of various subgroups of patients, the AIDS reporting system does make extensive use of national death registries in an attempt to obtain complete outcome information. With respect to the accuracy of the dates of onset of P. carinii pneumonia in the AIDS reporting system, there may be some delay between the actual date of onset and the date of reported onset; however, it is unlikely to be as uncertain as the date of onset of many other ADDS-defining conditions such as Kaposi's sarcoma or "low CD4 count" given that patients with P. carinii pneumonia are generally symptomatic. It was not possible to determine from the available data what effect, if any, expanded AIDS cases definitions may have had on the identification of P. carinii pneumonia patients because we did not include patients diagnosed after 1993 when the most significant AIDS case definition expansion was implemented (6) . Finally, no information was available in the present study to determine the length of time from initial HTV infection to the diagnosis of P. carinii pneumonia. Others (18, 19) have reported that the duration of HTV infection is not an important predictor of survival after adjustment for CD4 count. Despite these limitations, our findings strongly suggest significant temporal improvements in survival after P. carinii pneumonia diagnosis in California. The study, however, raises a question as to whether survival has continued to improve; during period 3 (March 1988 through June 1991), median survival after P. carinii pneumonia diagnosis appeared to oscillate consistently between 18 and 20 months (figure 1). Median survival for subsequent dates cannot yet be estimated. Whether more recently diagnosed patients indeed will have longer survival cannot be determined until more time has elapsed to allow complete reporting of deaths through the surveillance system. The available data do not preclude the possibilities that survival might have been much worse during period 3 had it not been for improvements in therapy and that the observed lack of change in survival during this period is a balancing of opposing forces. The improvement in survival during period 2 (July 1986 through March 1988) appears to have been greater for longterm survival (>12 months after diagnosis) than for short-term survival (3 and 6 months after diagnosis) (figure 2). This suggests that improvements in care for these patients for reasons other than acute treatment of P. carinii pneumonia were important. Unfortunately, surveillance databases do not permit an investigation of the isolated effects of the introduction of zidovudine and P. carinii pneumonia prophylactic agents such as cotrimoxazole and pentamidine, which were used widely in 1987 and 1988 (20) . Surveillance databases do, however, permit the evaluation of survival at a population level before and after the widespread introduction of therapeutic agents (18) .
The strong inverse trend in survival with age observed in this study has been reported in other investigations of AIDS patients in which more individual level patient data are available (18, 21, 22) . The present study did not find significant racial differences in survival in contrast to reports by others (17) . No change in long-term (3-year) survival after P. carinii pneumonia diagnosis was reported by Lundgren et al. (4) ; the present investigation did detect improvements in 2-year survival (figure 2) and in 3-year survival (data not shown).
One of the strongest predictors of survival in the present study was the presence of a CD4 count. This factor was more strongly associated with survival among patients with P. carinii pneumonia than was the actual level of the CD4 count itself. We are not aware of prior reports from public surveillance systems that have identified the importance of this marker, although uneven access to CD4 counts (which may be related to other aspects of the quality of health care) is likely to be a problem throughout the United States. The present investigation does not attempt to fully explore the differences in patient characteristics of these two groups; however, one might surmise from the data in table 4 that patients with CD4 counts reported were younger, more likely to have a definitive diagnosis of P. carinii pneumonia (implying that a diagnostic procedure was performed), and more likely to have come from San Francisco (where awareness of HIV/AIDS was great quite early in the epidemic) than were patients without CD4 counts. Although the presence of a CD4 count in a given patient is not itself a biologic phenomenon, it may well be strongly related to access to health care with its attendant early diagnosis and therapy and more intensive follow-up. Another possible relation between access to care and the availability of a CD4 count for a patient might be inferred from table 4: Among patients without a CD4 count, 49 percent received a definitive diagnosis of P. carinii pneumonia whereas among patients with a CD4 count, 96 percent received a diagnosis of P. carinii pneumonia (p < 0.001). It is likely that a definitive diagnosis of P. carinii pneumonia implies access to more extensive medical care because diagnostic procedures are required for classification as a definitive diagnosis. The magnitude of the differences in these two groups raises questions about whether more aggressive diagnostic intervention for all patients with suspected P. carinii pneumonia might truly increase survival or only lead to an apparent increase due to lead time bias (i.e., diagnosis earlier in the course of disease for the definitively diagnosed patients with no true impact on survival after onset of P. carinii pneumonia when compared with the presumptively diagnosed patients). The recursive partitioning analysis (figure 4), however, did not suggest that the certainty of diagnosis was an important correlate of survival after consideration of patient age and the availability of a CD4 count.
CD4 counts are frequently used by clinicians to guide antiretroviral therapy for HJV-infected patients. An alternative explanation for the differences in survival observed among the patients with and without available CD4 counts is that those patients without available CD4 counts were not receiving antiretroviral therapy. If this were true and if antiretroviral therapy prolonged survival, one would expect to observe longer survival times for those patients with reported CD4 counts.
The differences in survival seen across regions of California (tables 2-4) could be related to differences in access to care or management of HTV disease, which have been associated with survival in HTVinfected patients (23) . The present study does not include data with which to define the source of these regional differences in survival.
Increased understanding of the mechanisms by which the changes in survival observed in this investigation operate will help to determine whether more aggressive early intervention offers hope for improving survival after P. carinii pneumonia diagnosis. For patients with ADDS, new interventions such as protease inhibitors are currently being deployed rapidly, based on trials that enroll small numbers of patients in which the measured outcomes are surrogate markers (such as CD4 count or viral load) rather than clinical progression or survival (24). It will not be possible (within clinical trials) to examine whether these interventions have widespread impact on the survival of patients with AIDS: Patients may be unwilling to enroll in trials in which any arm of the study does not include a protease inhibitor if such drugs are widely believed to improve survival. In addition, years must elapse before measurement of any survival effect can occur. Observational data cannot be used to establish causal relations between the use of specific treatments and survival. If significant changes in survival are occurring, however, the full impact of such treatments on survival (in combination with all other concurrent changes in intervention and diagnosis) at a population level can be described only by the analysis of surveillance data. The present investigation suggests an improvement in survival after P. carinii pneumonia that is temporally consistent with the introduction and widespread use of zidovudine and cotrimoxazole. Despite these earlier improvements in survival after the diagnosis of P. carinii pneumonia, the long-term survival of these patients remains poor.
